Market Cap
$3.6B
XENE
Xenon Pharmaceuticals Inc.
$37.88 ▼ -2.68%
Prev close $38.93Market cap$3.6B
ConsensusStrong Buy
12-mo target$74.31 (+96.2%)
▲ Bullish
Analyst conviction 10/10
Insider Buying Cluster (2 insiders)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on XENE right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (96%)
Inst. Holders
50 funds
Inst. Value
$4.4B
Inst. Activity
32 buys / 18 sells
Insider Activity
$1.7M buy / $14.6M sell
Insider Net $
-$12.9M
SEC Reports
8
Press Releases
3
Price chart 30d -37.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: XENE — 55.3% short (0.9M / 1.6M)
Short: 893,302 | Exempt: 376 | TRF Vol: 1,616,288 | Short Ratio: 55.3% | Off-exchange volume (dark p
Sep 30, 2026 Insider
Kelly Thomas Patrick bought 15,000 shares
Chief Financial Officer @ $37.32 ($559.7K)
Sep 30, 2026 Insider
MORTIMER IAN bought 30,000 shares
PRESIDENT & CEO @ $37.38 ($1.1M)
Sep 1, 2026 Insider
Jul 2, 2026 Press Svoronos Dawn acquired via exercise 5,144 shares
Director @ $8.15 ($41.9K)
Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equit
Impact 1/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
7,522,482 shares ($454.1M)
Jun 30, 2026 Inst.
Jun 5, 2026 SEC JPMORGAN CHASE & CO — ADD
2,617,360 shares ($157.4M)
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued
144 — Impact 2/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
96% rate it Buy or better · 26 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 18, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Sep 18, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Sep 18, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Sep 18, 2026 | Deutsche Bank | DOWNGRADE | Hold | 58% |
| Sep 18, 2026 | Needham | MAINTAIN | Buy | 50% |
| Sep 18, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| May 27, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Aug 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Jul 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Jun 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 10 | 15 | 1 | 0 | 0 | 96% |
Price targets
Where 18 covering analysts think XENE trades over the next 12 months.
$74.31 +96.2% upside Strong Buy
Current$37.89 Low$46.00 Median$74.50 High$97.00 18 analysts
$46.00$97.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 3 bearish, 1 mixed, 4 neutral · avg impact 4.0/10.Plus 3 press releases.
NEUTRAL1442/10
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals
Jun 5, 2026
NEUTRAL8-K3/10
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where s
Jun 3, 2026
MIXEDPRESS-RELEASE6/10
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in
May 7, 2026
NEUTRALDEFA14A2/10
Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the
Apr 22, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: XENE — 55.3% short (0.9M / 1.6M)
Short: 893,302 | Exempt: 376 | TRF Vol: 1,616,288 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: XENE — 55.2% short (0.5M / 1.0M)
Short: 529,813 | Exempt: 9,350 | TRF Vol: 959,595 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
other
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical c
Sep 21, 2026
Clinical Trial
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
Phase Phase 2 — COMPLETED
Sep 17, 2026
other
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical c
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.15 | $-1.29–$-0.94 | -0.0% | +0.7% | 9↑ 4↓ | $0.0B | 13 |
| Next Q | $-1.17 | $-1.35–$-0.85 | 10.7% | +0.8% | 10↑ 3↓ | $0.0B | 13 |
| Current FY | $-4.63 | $-4.93–$-4.06 | -6.2% | +0.1% | 11↑ 2↓ | $0.0B | 14 |
| Next FY | $-4.71 | $-5.50–$-1.90 | -1.9% | +3.1% | 7↑ 5↓ | $0.0B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.150 | — |
| 7d ago | $-1.150 | — |
| 30d ago | $-1.159 | +0.009 |
| 60d ago | $-1.194 | +0.044 |
| 90d ago | $-1.194 | +0.044 |
Institutional ownership
Which big funds own XENE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.4B total value (72,252,579 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 9,647,998 | $582.4M | 13.4% | — |
| BlackRock, Inc. | 7,522,482 | $454.1M | 10.4% | ADD +33.4% |
| Avoro Capital Advisors LLC | 5,777,777 | $348.7M | 8.0% | — |
| Polar Capital Holdings Plc | 4,570,556 | $275.9M | 6.3% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,418,557 | $266.7M | 6.1% | — |
| Jupiter Topco LLC | 4,186,519 | $252.7M | 5.8% | — |
| JPMORGAN CHASE & CO | 2,617,360 | $157.4M | 3.6% | ADD +36.1% |
| Capital International Investors | 2,361,639 | $142.5M | 3.3% | — |
| STATE STREET CORP | 1,969,629 | $118.9M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 5,640,118 | 7,522,482 | +33.4% | $454.1M |
| JPMORGAN CHASE & CO | ADD | 1,923,610 | 2,617,360 | +36.1% | $157.4M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 4,829,641 | 1,425,492 | -70.5% | $86.0M |
| CITADEL ADVISORS LLC | TRIM | 2,652,990 | 1,401,242 | -47.2% | $84.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,092,932 | 1,370,114 | +25.4% | $82.7M |
| Pictet Asset Management Holding SA | ADD | 679,709 | 1,187,723 | +74.7% | $71.6M |
| Nuveen, LLC | DOUBLED | 250,036 | 993,126 | +297.2% | $59.9M |
| AMERICAN CENTURY COMPANIES INC | ADD | 679,314 | 884,319 | +30.2% | $53.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 543,062 | 749,651 | +38.0% | $45.2M |
| Alyeska Investment Group, L.P. | TRIM | 1,299,469 | 697,692 | -46.3% | $42.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net -$12.9M — $1.7M bought, $14.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Kelly Thomas Patrick | Chief Financial Officer | BUY | 15,000 | $37.32 | $559.7K |
| Sep 30, 2026 | MORTIMER IAN | PRESIDENT & CEO | BUY | 30,000 | $37.38 | $1.1M |
| Sep 1, 2026 | Svoronos Dawn | Director | EXERCISE | 5,144 | $8.15 | $41.9K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 6,368 | $60.17 | $383.1K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 700 | $60.98 | $42.7K |
| Aug 11, 2026 | GANNON STEVEN | Director | SELL | 10,000 | $64.06 | $640.6K |
| Jun 5, 2026 | Cannon Gillian | Director | SELL | 1,190 | $53.14 | $63.2K |
| Jun 5, 2026 | PATOU GARY | Director | SELL | 1,322 | $53.14 | $70.3K |
| Jun 3, 2026 | Gover Justin D. | Director | AWARD | 10,507 | — | — |
| Jun 3, 2026 | Machado Patrick | Director | AWARD | 10,507 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for XENE.
Shares short
6,444,815
Settlement Sep 15, 2026
Change vs prior
+1.6%
Semi-monthly cycle
Days to cover
12.2
At avg daily volume
Of shares outstanding
≈6.7%
Estimate — not % of float
All XENE filing & press-release reports (11)
- PRESS-RELEASE reportJul 2, 2026
- 144 reportJun 5, 2026
- 8-K reportJun 3, 2026
- PRESS-RELEASE reportMay 7, 2026
- DEFA14A reportApr 22, 2026
- PRESS-RELEASE reportApr 19, 2026
- PRESS-RELEASE reportApr 15, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 7, 2026
- CLUSTER reportMar 14, 2026
- PRESS-RELEASE reportMar 12, 2026